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innate immune activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity
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NKTR-214/NKTR-262 treatment improves abscopal responses through a CD8 T cell dependent mechanism
Combining local RT with immunotherapy such as NKTR-214, a CD122-biased cytokine 
agonist conjugated with releasable polyethylene-glycol (PEG) chains, increases abscopal 
response rates, but still leaves room for improvement.
The biologic mechanism driving the abscopal response is yet to be fully understood, but 
immunosuppression is throught to contribute to low abscopal response rates.
Finally, comparison of NKTR-214 combined with either RT or NKTR-262, will reveal 
mechanisms driving abscopal responses.
We hypothesized that combination treatment with a novel TLR7/8 targeting agent, NKTR-262, 
with NKTR-214 will activate innate and adaptive anti-tumor immune responses that will 
increase abscopal tumor responses.
Toll-like receptor (TLR) signaling can induce APC differentiation and reduce tumor 
microenvironment immune suppression.
The abscopal effect refers to the ability of localized radiation to trigger systemic anti-tumor 
effects. However, with radiation therapy (RT) alone, the abscopal effect is exceedingly rare.
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Peripherial blood CD8 T cell responses correlate with overall tumor burden
Intratumoral CD8 T cell responses correlate with tumor burden 
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Mice bearing dual flank 
CT-26 tumors were treated as 
described in the methods.
Tumor area (mm2) was 
determined every 2-3 days on 
the treatment and abscopal 
sides (grey boxes). 
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combination treatment 
significantly reduced tumor 
growth and increased 
survival (top center). 
This response depends 
primarily on CD8 cells as 
depletion of CD8s (yellow 
diamond) but not CD4 
(maroon square),  abrogated 
the effect. N>10 from two 
independent experiments.
NKTR-214/NKTR-262 TME favors M1 monocytes
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Introduction
Methods
ConclusionsNKTR-214/NKTR-262 induces less exhausted and more active CD8 T cell responses 
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7 days post treatment, peripherial blood was collected, and T cell phenotypes were determined by 
flow cytometry (top row). Statistical significance was determined using a 1-way ANOVA comparing all 
groups against NKTR-214/NKTR-262, with a p-value cut-off of 0.05.
Cell percentages were compared to total tumor burden using Spearman correlation to identify which 
cell types may impact tumor size (bottom row and heat map).
Nearly all CD8 cell phenotypes in the periphery correlate with total tumor burden 7 days post 
treatment (heat map below). N>12 from two independent experiments.
NKTR-214/NKTR-262 combination treatment 
resulted in CD8 T cells with reduced expression 
of exhaustion markers PD-1, Tim3, and Lag3. 
Further, tumor reactive CD8 T cells (AH1-A5+) 
also had reduced expression of PD-1. N>8 from 
two independent experiments.
Statistical significance was determined using 
Students T Test between the two combination 
groups.
 Data is presented as percent of population or a ratio of %M1/%M2 based on iNOS and Arg1 expression. N>4 from one experiment.
NKTR-214/NKTR-262 combination treatment resulted in monocytic cells (CD11b+Ly6C+Ly6G-) with increased iNOS expression, 
and by extention an increased M1/M2 ratio. 
The data suggests that NKTR-262 may alter the TME to be less suppressive, thereby supporting a more effective adaptive response. 
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Nur77:GFP+ mice bearing dual flank CT-26 
tumors treated with NKTR-214/NKTR-262 had  
a greater tumor CD8+ Nur77+ cell density, 
which also expressed increased GzmA levels.
 
NKTR-214/NKTR-262 induces more functional  
cells, which is represented by a relationship 
between those cells and tumor size in the 
NKTR214/NKTR-262 treated mice. N=4 from 
one expt.
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Data is presented as percent of population (top row) and cell 
density (bottom row). Statistical significance was determined using 
Students T Test between the two combination groups.
Cell densities were compared to tumor burden for the treated and 
abscopal tumor (heat map below).
CD8 T cell responses correlate strongly with abscopal tumor size 
NKTR-214/NKTR-262 significantly increases the abscopal responses in comparison to 
NKTR-214/RT combination therapy in a CD8 T cell dependent manner.
Across all treatment groups, peripherial CD8 T cells correlate with tumor burden 7 days post 
treatment.
NKTR-214/NKTR-262 combination treatment results in an increased density of CD8 T cells in both 
the treated and abscopal tumor. These CD8 T cells have increased GzmA expression and reduced 
conversion to an exhausted phenotype (PD-1, Tim3, Lag3). 
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Using flow cytometry we evaluated CD4+, CD8+, and NK cell activation status  in the blood 
and tumor 7 days post-treatment and we evaluted innate immune subsets (macrophages, 
monocytes) including M1/M2 polarization 1 day post-treatment. To determine the contribution 
of each cell type, mice were treated with depleting antibodies 1x/week.
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These active CD8 T cells are supported by a less suppressive tumor microenvironment, 
demonstrated by the increased M1/M2 monocytic ratio in NKTR-214/NKTR-262 treated animals.
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